Skip to main content
TipRanks
Go Ultimate75% OFF

Profusa (PFSA) AI Stock Analysis

110 Followers
PFSA

Profusa

(NASDAQ:PFSA)

Select Model
Rating:39Underperform
Price Target:$0.42â–²(4.44% Upside)
Action:reiterated
Date:11/16/26

PFSA scores near the bottom of the range, driven primarily by a high-risk, binary financial profile: no revenue in any reported period, a $25.7M trailing-twelve-month net loss, and roughly $12M of annual cash burn against a thin $7.8M equity cushion. Technicals reinforce the caution, with the stock trading far beneath all major moving averages and momentum still negative. Valuation offers no support given negative earnings and no dividend. Partial offsets include a materially improved capital structure — equity restored to positive territory, debt cut to $6.5M, and $6.14M of notes converted to preferred stock — plus confirmed Nasdaq compliance; however, continued reliance on small, dilutive secured convertible financings keeps shareholder dilution risk elevated.

Positive Factors
Biosensor PlatformThe tissue-integrated sensor platform addresses continuous, real-time physiological monitoring through an implantable device and external reader. Its potential applications across health monitoring and performance tracking provide multiple commercialization pathways if the technology advances into broader product adoption.
Negative Factors
No Revenue and Widening LossesThe absence of reported revenue across periods indicates that commercialization has not yet produced measurable operating scale. At the same time, the much larger TTM loss shows deteriorating earnings performance, leaving the business dependent on future product progress and external capital to reach profitability.

Profusa (PFSA) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%PFSA-99.97%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.89M
Dividend Yield
―
Average Volume (3M)
3.56M
Price to Earnings (P/E)
-0.0
Beta (1Y)
1.20
Revenue Growth
―
EPS Growth
96.27%
Country
US
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Profusa Business Overview & Revenue Model

Company Description

Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor comp...

How the Company Makes Money

Profusa’s primary monetization model is expected to center on commercialization of its biosensing products and associated system components (e.g., implantable sensor units and external readers/wearables) and, where applicable, related services or sof...

Profusa Financial Statement Overview

Summary

Profusa is a pre-revenue, development-stage medical device company with zero reported revenue across all periods and widening losses, peaking at a $35.8M net loss in 2025 and $25.7M on a trailing-twelve-month basis. Cash flow is the weakest link: operating and free cash flow have been negative every year, with roughly $12M burned over the last twelve months and almost no capital spending to offset, meaning losses convert directly into cash outflows. The one bright spot is the balance sheet, where a recapitalization lifted shareholders' equity from deeply negative levels to a positive $7.8M, grew assets to $28.9M and cut debt to $6.5M (0.83x debt-to-equity). Even so, the equity cushion covers only a limited runway at the current burn rate, leaving the company reliant on continued external financing.

Income Statement

6Very Negative

Balance Sheet

27Negative

Cash Flow

9Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-7,00000000
EBITDA-19.32M-30.73M-4.81M-6.00M-13.22M-5.05M
Net Income-25.73M-35.82M-9.23M-10.28M-20.22M-10.31M
Balance Sheet
Total Assets28.89M3.77M3.07M1.89M1.03M11.36M
Cash, Cash Equivalents and Short-Term Investments339.00K1.78M191.00K142.00K78.00K856.00K
Total Debt6.47M14.81M48.21M40.40M31.03M24.02M
Total Liabilities21.09M30.43M122.28M111.89M100.80M95.02M
Stockholders Equity7.79M-26.66M-119.20M-110.00M-99.77M-83.66M
Cash Flow
Free Cash Flow-12.10M-16.26M-2.07M-4.40M-7.70M-10.69M
Operating Cash Flow-12.02M-16.25M-2.07M-4.40M-7.70M-10.69M
Investing Cash Flow63.00K-2.01M0-2,00000
Financing Cash Flow9.28M19.84M2.12M4.47M6.92M8.75M

Profusa Technical Analysis

Technical Analysis SentimentNegative
Last Price0.41

Price Trends

50DMA1.38Negative
100DMA4.06Negative
200DMA52.72Negative

Market Momentum

MACD-0.32Negative
RSI30.99Neutral
STOCH10.02Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFSA, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 1.38, and below the 200-day MA of 52.72, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 30.99 is Neutral, neither overbought nor oversold. The STOCH value of 10.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFSA.

Profusa Risk Analysis

Profusa disclosed 86 risk factors in its most recent earnings report. Profusa reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Holders of our Series A Non-Voting Convertible Preferred Stock may experience significant dilution upon conversion, and we may be required to redeem such shares for cash if stockholder approval for conversion is not obtained.Q2, 2026
2.Dilution from warrant exerciseQ2, 2026
3.Our proposed acquisition of G3 Vision Labs Inc. and its subsidiaries is subject to numerous conditions and may not be completed on the terms currently contemplated, or at all.Q2, 2026

Profusa Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PFSA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$131.60B25.2710.60%2.78%9.77%12.28%
DXCMDXCM73Outperform$30.44B31.6136.50%―13.03%40.88%
ABTABT67Neutral$186.10B39.969.11%2.35%10.00%-66.06%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SENSSENS50Neutral$597.11M-4.72-186.15%―104.83%-37.15%
OWLTOWLT45Neutral$97.44M-5.54-34.25%―13.74%78.29%
PFSAPFSA39Underperform$245.71K-0.00138.72%――96.27%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%PFSAABTDXCMMDTSENSOWLTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PFSA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PFSAProfusa, Inc.0.41-1347.35-99.97%
ABTAbbott Laboratories107.45-19.40-15.29%
DXCMDexcom81.6121.4435.63%
MDTMedtronic102.885.315.45%
SENSSenseonics Holdings Inc.10.904.9282.27%
OWLTOwlet Inc3.26-9.16-73.75%

Profusa Corporate Events

Private Placements and FinancingRegulatory Filings and Compliance

Profusa Amends Promissory Note Conversion Pricing Terms

Neutral
Nov 6, 2026

Profusa, Inc. and NorthView Sponsor I LLC amended a promissory note originally carrying principal of up to $2.5 million. On November 5, 2026, the Fourth Amendment set the conversion price at the greater of $0.20 or the Nasdaq closing price on the tra...

Business Operations and StrategyPrivate Placements and Financing

Profusa Issues Convertible Secured Note in Private Financing

Negative
Oct 15, 2026

On October 15, 2026, Profusa issued a senior secured convertible promissory note to Ascent Partners Fund LLC with a principal amount of $769,230.77 for a purchase price of $700,000.00 under an existing securities purchase agreement. The note bears 7%...

Business Operations and StrategyPrivate Placements and Financing

Profusa Amends Convertible Notes and Financing Terms

Neutral
Oct 5, 2026

On October 4, 2026, Profusa amended two senior secured convertible promissory notes originally issued to Ascent Partners Fund LLC on April 2, 2026 and April 20, 2026, with maturities in 2027, altering key economic terms of the securities. The convers...

Business Operations and StrategyPrivate Placements and Financing

Profusa Adds Secured Convertible Debt Financing Agreement

Neutral
Sep 16, 2026

On September 16, 2026, Profusa completed an additional closing under its February 11, 2025 Securities Purchase Agreement with Ascent Partners Fund LLC, issuing a senior secured convertible promissory note with a principal amount of $384,615.38 for a...

Delistings and Listing ChangesRegulatory Filings and Compliance

Profusa Regains Nasdaq Compliance, Enters One-Year Monitoring

Neutral
Sep 15, 2026

On September 9, 2026, Profusa, Inc. received confirmation from Nasdaq that it had regained compliance with the Bid Price and Equity listing rules. The determination removes the immediate threat of delisting but places the company under a one-year Man...

Business Operations and StrategyPrivate Placements and Financing

Profusa Secures New Convertible Note Financing Agreement

Neutral
Sep 1, 2026

On September 1, 2026, Profusa, Inc. completed an additional closing under a February 11, 2025 securities purchase agreement and issued Ascent Partners Fund LLC a senior secured convertible promissory note with a principal amount of $329,670.33 for a...

Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split

Profusa Confirms Continued Compliance With Nasdaq Listing Standards

Positive
Aug 31, 2026

On August 26, 2026, Profusa disclosed that Nasdaq’s Listing Qualifications Department had initially notified the company that its recent 1-for-4 reverse stock split left it with fewer than the 500,000 publicly held shares required under Nasdaq Listin...

Business Operations and StrategyPrivate Placements and Financing

Profusa Strengthens Capital Structure Through Debt-to-Equity Exchange

Positive
Aug 21, 2026

On August 12, 2026, Profusa entered into a fifth amendment to its 2025 securities purchase agreement with Ascent Partners Fund, updating the amendment effective date, adding a new optional note form and resetting the exercise price of an existing war...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026